A Phase 2 Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038) in Combination With Sargramostim (GM-CSF) in Patients With Recurrent Osteosarcoma
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Dinutuximab (Primary) ; Sargramostim
- Indications Osteosarcoma
- Focus Therapeutic Use
- 26 Jul 2017 Status changed from suspended to recruiting.
- 10 Jun 2017 Biomarkers information updated
- 13 Mar 2017 Status changed from recruiting to suspended due to Pending evaluation of 2 SAEs.